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Cardiac biomarkers of prognostic
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pulmonary disease
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Eva Rönmark5, Takeshi Fujisawa2, Anders Blomberg1 and Anne Lindberg1
Abstract
Ischemic heart disease is common in COPD and associated with worse prognosis. This study aimed to investigate
the presence and prognostic impact of biomarkers of myocardial injury and ischemia among individuals with COPD
and normal lung function, respectively.
Methods: In 2002–04, all individuals with airway obstruction (FEV1/VC < 0.70, n = 993) were identified from
population-based cohorts, together with age and sex-matched non-obstructive referents. At re-examination in 2005,
spirometry, Minnesota-coded ECG and analyses of high-sensitivity cardiac troponin I (hs-cTnI) were performed in
individuals with COPD (n = 601) and those with normal lung function (n = 755). Deaths were recorded until
December 31st, 2010.
Results: Hs-cTnI concentrations were above the risk stratification threshold of ≥5 ng/L in 31.1 and 24.9% of those
with COPD and normal lung function, respectively. Ischemic ECG abnormalities were present in 14.8 and 13.4%,
while 7.7 and 6.6% had both elevated hs-cTnI concentrations and ischemic ECG abnormalities. The 5-year
cumulative mortality was higher in those with COPD than those with normal lung function (13.6% vs. 7.7%, p <
0.001). Among individuals with COPD, elevated hs-cTnI both independently and in combination with ischemic ECG
abnormalities were associated with an increased risk for death (adjusted hazard ratio [HR]; 95% confidence interval
[CI] 2.72; 1.46–5.07 and 4.54; 2.25–9.13, respectively). Similar associations were observed also among individuals with
COPD without reported ischemic heart disease.
Conclusions: In this study, elevated hs-cTnI concentrations in combination with myocardial ischemia on the
electrocardiogram were associated with a more than four-fold increased risk for death in a population-based COPD-
cohort, independent of disease severity.
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Background
Chronic Obstructive Pulmonary Disease (COPD) is a
common but under-diagnosed disease [1, 2]. In COPD,
there is an increased risk for concomitant cardiovascular
disease [3] and cardiovascular comorbidity is associated
with increased mortality [4]. Still, patients with COPD
may be less likely to receive cardiovascular preventative
therapies [5], albeit most guidelines for diagnosis and
treatment of COPD [6] include recommendations re-
garding evaluation of cardiovascular risk factors and the
presence of cardiovascular disease. However, no bio-
marker has been shown to identify subclinical cardiovas-
cular disease in a representative population-based cohort
of individuals with COPD, even though ischemic abnor-
malities on electrocardiogram (ECG) are suggested to be
associated with worse prognosis [7].
Cardiac troponins are specific markers of myocardial
injury and are used universally for the diagnosis of myo-
cardial infarction [8]. High-sensitivity cardiac troponin I
(hs-cTnI) assays have limits of detection 10 to 100-fold
lower than contemporary assays and can detect troponin
in the majority of healthy individuals [9]. Hence, these
assays may identify patients with subclinical cardiac dis-
ease [10], using risk stratification thresholds well below
those used to diagnose myocardial infarction [11, 12].
Recently published data suggest that a risk stratification
threshold of < 5 ng/L can identify patients with chest
pain at low risk of having cardiac events [11] and, fur-
ther, is able stratify patients with stable COPD and con-
comitant cardiovascular risk factors into low and high-
risk groups [13]. Increased troponin levels are also asso-
ciated with poor prognosis in patients with acute exacer-
bations of COPD [14, 15]. One recent study, including
stable patients with mainly moderate and severe COPD,
also showed a correlation between hs-cTnI ≥6 ng/L and
poor prognosis [16]. However, this has rarely been evalu-
ated in population-based COPD-studies. Based on these
observations, we hypothesise that hs-cTnI concentra-
tions reflect subclinical heart disease and may help to
guide prognosis among individuals with COPD in the
population. If this hypothesis is confirmed, hs-cTnI test-
ing could be used more widely to identify individuals
with COPD at increased risk.
The aim of this study was to evaluate hs-cTnI concen-
trations among individuals with COPD and individuals
with normal lung function to determine the prognostic
value of hs-cTnI. A secondary aim was to include ische-
mic ECG abnormalities in the risk assessment.
Methods
Study design and study population
The study design of the Obstructive Lung Disease in
Northern Sweden (OLIN) COPD study has previously
been described in detail [7, 17]. In summary, the COPD
population in this study (n = 993) was identified after re-
examination including spirometry of four previously re-
cruited population-based cohorts in 2002–04 (n = 4200),
together with n = 993 non-obstructive referents matched
by age and sex. The study population has since 2005
been invited to annual examinations. The original age
and sex-matching at recruitment was not maintained
during the annual follow-ups. This paper includes data
from 2005, when complete data on 12-lead ECG and
blood samples were collected from 1356 participants, in
addition to spirometry and structured interviews (n =
601 COPD, n = 755 with normal lung function). Mortal-
ity data from the Swedish Tax Agency were obtained
from the date of examination until 31st December 2010
and causes of death were collected from the Swedish
National Board of Health and Welfare.
Definitions
Smoking habits and prevalence of comorbidities were
categorized based on interview data [7]. Blood samples
were stored at − 20 °C and were thawed and analysed in
2017. Analyses were performed with the ARCHITECT
STAT high-sensitivity cardiac troponin I (hs-cTnI) assay
(Abbott Laboratories, Abbott Park, IL) at the BHF Bio-
marker Lab in the University of Edinburgh, with a lower
limit of detection of 1.2 ng/L, an upper reference limit of
34 ng/L in men and 16 ng/L in women and a coefficient
of variation < 10% at 4.7 ng/L [12].
Standard 12-lead ECGs were recorded and classified ac-
cording to the Minnesota code [18] by two independent
encoders. Myocardial ischemic abnormalities defined by
Minnesota coding were grouped together [7], hereafter re-
ferred to as “ischemic ECG abnormalities” (I-ECG).
Individuals with COPD and normal lung function were
categorized, with respect to the cardiac biomarkers, into
the following groups: no cardiac biomarkers (hs-cTnI <
5 ng/L and no ischemic ECG abnormalities), hs-cTnI >
5 ng/L alone, ischemic ECG abnormalities alone, and
both hs-cTnI > 5 ng/L and ischemic ECG abnormalities
(Fig. 1 a-b).
The fixed ratio criterion was used to define airway ob-
struction corresponding to COPD. The spirometry in-
cluded measurement of FEV1 (forced expiratory volume
1 s), FVC (forced vital capacity) and SVC (slow vital cap-
acity) and was conducted according to the 1994 ATS
guidelines [19]. The highest of FVC and SVC was used
to define VC (vital capacity). If FEV1/VC was < 0.70 or
FEV1 < 80% of predicted, post-bronchodilator spirometry
was performed after the inhalation of Ventoline discus®
4 × 0.2 mg. COPD was spirometrically defined as FEV1/
VC < 0.70 using the highest values extracted from all of
the acceptable spirometry curves for each of the parame-
ters [20, 21]. FEV1 reversibility was not assessed or a
part of the estimation of airway obstruction, however,
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FEV1 percent of predicted (highest obtained value) was
used to assess the severity of airflow limitation, further
divided into grade 1–4 according to GOLD [6], among
those fulfilling the spirometric criteria for COPD by the
fixed ratio. In the non-obstructive reference population
(FEV1/VC ≥0.70), those with normal lung function
(FEV1/VC ≥0.70 and FVC > 80% of predicted) were iden-
tified. The OLIN reference values were used [22].
Statistics
Statistical analyses were performed using SPSS version
25 (IBM, Armonk, NY, USA). Categorical variables were
compared using chi-square test, independent sample t-
test to compare means and Mann-Whitney U-test to
compare medians. Survival in each of the groups was ex-
amined by plotting Kaplan-Meier curves. Mortality rate
was estimated as the number of deaths per 1000 person-
years. Cardiac biomarkers were evaluated as risk factors
for death expressed as Hazard Ratios (HR) and 95%
Confidence Intervals (95% CI) in bivariate analyses and
multivariate Cox models adjusting for age, sex, smoking
habits, diabetes mellitus and FEV1% predicted. Kaplan
Meier curves and forest plots were created using Graph-
Pad Prism version 8.4 (GraphPad Software, San Diego,
CA, USA).
Results
The baseline characteristics of individuals with COPD
(n = 601) and those with normal lung function (n = 755)
are presented in Table 1. Among those with COPD,
41.6, 51.1 and 7.3% were classified as GOLD grades 1, 2
and 3–4 respectively. The prevalence of reported ische-
mic heart disease was higher among individuals with
a
c d
b
Fig. 1 Prevalence of and mortality by cardiac biomarker categories based on hs-cTnI and/or ischemic ECG abnormalities (I-ECG). The prevalence
of cardiac biomarker categories is illustrated by Venn diagrams in individuals with a COPD (n = 601) and b normal lung function (NLF) (n = 755),
respectively. The cumulative mortality by cardiac biomarker category is illustrated by bar charts among individuals with c COPD and d NLF. (I-ECG
includes Major Q/QS wave, major isolated ST-T abnormality, Minor Q wave plus major ST-T and minor isolated Q wave)
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COPD (17.1%) compared to individuals with normal
lung function (12.5%).
Troponin concentrations were above the limit of de-
tection in 580 (96.5%) individuals with COPD and 708
(93.8%) individuals with normal lung function and were
above the upper reference limit in 20 individuals with
COPD and 24 individuals with normal lung function
(3.3 and 3.2%, respectively). The median hs-cTnI con-
centration and proportion of individuals with hs-cTnI >
5 ng/L were higher in COPD than in normal lung func-
tion (Table 1).
In both individuals with COPD and those with normal
lung function, hs-cTnI concentrations > 5 ng/L were associ-
ated with higher age, male sex, and higher proportions of
diabetes mellitus and ischemic heart disease (see Supplemen-
tary Table 1, Additional File 1). Analyses in an adjusted
model confirmed that age and sex remained significantly as-
sociated with hs-cTnI ≥5 ng/L in both COPD and NLF, to-
gether with ischemic heart disease in the COPD group and
ischemic ECG abnormalities in the NLF group (see Supple-
mentary Table 2, Additional File 1).
The prevalence of ischemic ECG abnormalities was
similar among individuals with COPD and those with
normal lung function, 14.8 and 13.4% respectively
(Table 1). The proportion with ischemic ECG abnor-
malities was higher among those with hs-cTnI > 5 ng/L
than among those with hs-cTnI < 5 ng/L in both groups
(24.6% vs. 10.4, and 26.6% vs. 9.0% respectively; p <
0.001 for both, see Supplementary Table 1, Additional
File 1). Among individuals with COPD, 23.5% had hs-
cTnI > 5 ng/L alone, 7.2% had ischemic ECG abnormal-
ities alone and 7.7% had both hs-cTnI > 5 ng/L and
Table 1 Basic characteristics of the study population, comparing individuals with COPD and normal lung function (NLF)
Category Variables COPD (n = 601) NLF (n = 755) p
Age Age, mean (SD) 67.0 (10.6) 64.5 (11.3) < 0.001
Sex Women 253 (42.1) 361 (47.8) 0.036
Smoking habits < 0.001
Never smoker 153 (25.5) 354 (46.9)
Ex-smoker 250 (41.6) 303 (40.1)
Current smoker 198 (32.9) 98 (13.0)
BMI groups 0.025
BMI < 20 20 (3.3) 12 (1.6)
BMI 20–24.9 206 (34.3) 238 (31.5)
BMI 25–29.9 279 (46.4) 347 (46.0)
BMI ≥30 96 (16.0) 158 (20.9)
Oxygen saturation Saturation percent, mean (SD) 96.2 (2.2) 97.1 (1.3) < 0.001
Hypoxemia (< 92%) 8 (1.3) 0 (0) 0.001
Exacerbations Hospital admission last 12 months1 11 (1.8) 11 (1.5) 0.589
Comorbidities Diabetes mellitus 54 (9.0) 64 (8.5) 0.742
Angina pectoris 76 (12.2) 80 (10.6) 0.240
Myocardial infarction 35 (5.8) 19 (2.5) 0.002
CABG and/or PCI 23 (3.8) 34 (4.5) 0.538
Ischemic heart disease2 103 (17.1) 94 (12.5) 0.015
ECG Ischemic abnormalities3 89 (14.8) 101 (13.4) 0.451
hs-cTnI hs-cTnI, ng/L median (IQR)4 3.3 (3.6) 3.2 (2.9) 0.019
hs-cTnI ≥5 ng/L, % 187 (31.1) 188 (24.9) 0.011
Lung function FEV1% of predicted value, mean (SD) 75.8 (16.4) 98.0 (10.8) < 0.001
GOLD 1 250 (41.6) n/a
GOLD 2 307 (51.1) n/a
GOLD 3–4 44 (7.3) n/a
Presented as n (%) unless otherwise stated. Significant values in bold
1Hopsitalization due to respiratory condition
2Including angina pectoris, myocardial infarction, coronary artery bypass grafting (CABG) and/or percutaneous coronary intervention (PCI)
3Including Major Q/QS wave, major isolated ST-T abnormality, Minor Q wave plus major ST-T and minor isolated Q wave based on Minnesota coding
4Mann-Whitney U test, interquartile range (IQR)
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ischemic ECG abnormalities, while the corresponding
prevalence among those with normal lung function was
18.3, 6.8 and 6.6% respectively (Fig. 1 a-b).
Mortality
In total, 140 individuals died during the observation
period; 82 with COPD and 58 with normal lung function
(13.6% vs 7.7%, p < 0.001), corresponding to a mortality
rate of 27 and 15 per 1000 person-years respectively. In
the COPD-group, 54/82 or 66% of deaths were due to
cardiovascular disease compared with 35/58 or 60% of
the deaths in the normal lung function group. The cu-
mulative mortality was higher among those with hs-cTnI
> 5 ng/L than those with hs-cTnI < 5 ng/L in both
groups (see Supplementary Table 1, Additional File 1).
Likewise, in both groups, the cumulative mortality was
higher among those with, compared to those without, is-
chemic ECG abnormalities (30.3% vs. 10.7%, p < 0.001
and 17.8% vs. 6.1%, p < 0.001 respectively).
Among individuals with COPD, the cumulative mor-
tality was 26.5% in those with hs-cTnI > 5 ng/L alone,
16.3% in those with ischemic ECG abnormalities alone
and 43.5% in those with both hs-cTnI > 5 ng/L and is-
chemic ECG abnormalities. The corresponding rates in
those with normal lung function were 10.9, 9.8 and
26.0% (Fig. 1 c-d). Within each of these biomarker
groups, the corresponding proportions deceased due to
cardiovascular disease were in COPD 69, 71 and 70% re-
spectively (with a proportion of 53% among those with-
out any of these biomarkers). The equivalent
proportions in the normal lung function group were 60,
40 and 77% respectively, (56% without any of the
biomarkers).
Survival by cardiac biomarker group is illustrated by
Kaplan Meier curves among individuals with COPD and
those with normal lung function, respectively (Fig. 2a-b).
Among individuals with COPD, the mortality rate
amongst those without any cardiac biomarkers was 10
per 1000 person-years. The corresponding mortality
rates per 1000 person-years were 52 in those with a hs-
cTnI ≥5 ng/L alone, 31 in those with ischemic ECG ab-
normalities alone, and 103 in those with both hs-cTnI >
5 ng/L and ischemic ECG abnormalities. In individuals
with normal lung function, the corresponding mortality
rates were 9, 21, 19 and 53 per 1000 person-years.
Among individuals with COPD and hs-cTnI > 5 ng/L
alone and those with both hs-cTnI > 5 ng/L and ische-
mic ECG abnormalities, the risk for death was increased
after adjustment for potential confounders (HR 2.72,
95% CI 1.46–5.07; HR 4.54, 95% CI 2.25–9.13 respect-
ively) when compared to those with no cardiac bio-
markers (Fig. 3a). The risk for death was increased,
independent of disease severity assessed as FEV1% pre-
dicted (see Supplementary Table 3, Additional File 1). In
corresponding analyses among subjects with normal
lung function, ischemic ECG abnormalities alone
seemed to be of greater importance than cTnI > 5 ng/L
alone (Fig. 3b).
Participants without reported ischemic heart disease
In analyses restricted to participants without reported is-
chemic heart disease, 72.9 and 87.5% of those with
COPD and normal lung function respectively, similar
associations were found for all analyses (see Supplemen-
tary Fig. 1 and Supplementary Table 4, Additional File
1). Among individuals with COPD, hs-cTnI > 5 ng/L
alone as well as having both hs-cTnI > 5 ng/L and ische-
mic ECG abnormalities were associated with an in-
creased the risk for death independent of confounders
and disease severity (see Supplementary Table 4, Add-
itional File 1).
Discussion
In this study, a history of ischemic heart disease, myo-
cardial injury and myocardial ischemia was common and
more frequent among individuals with COPD than
among individuals with normal lung function. As ex-
pected, mortality was higher among individuals with
COPD than among those with normal lung function,
and high-sensitivity cardiac troponin was associated with
increased mortality in both groups. An elevated hs-cTnI
concentration with or without signs of myocardial ische-
mia on ECG increased the risk for death three- to four-
fold among individuals with COPD, independent of age,
sex, smoking habits, diabetes mellitus and disease sever-
ity. Importantly, these cardiac biomarkers were associ-
ated with an increased risk for death of similar
magnitude also among individuals with COPD without
known ischemic heart disease.
Even though individuals with COPD comprise a high-
risk population, ischemic heart disease is often-
overlooked, but the converse is also true, as COPD is
often undiagnosed in patients with ischemic heart dis-
ease [23]. Most current guidelines for the diagnosis and
treatment of COPD highlight the need for greater aware-
ness of cardiovascular risk and comorbidities among pa-
tients with COPD, in order to initiate preventive
measures and optimise outcomes. However, there are no
specific recommendations for the approach to risk as-
sessment of ischemic heart disease among individuals
with COPD.
In a large-scale multi-center study including > 16,000
patients with COPD and cardiovascular disease or risk
factors for cardiovascular disease, acute exacerbations of
COPD (AECOPD) were associated with an increased
risk for new cardiovascular events, including cardiovas-
cular death [24]. Cardiac troponin has over time been
proven to be an independent risk factor for all-cause
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Fig. 2 (See legend on next page.)
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mortality during acute exacerbation of COPD [14].
Troponin, as well as NT-proBNP, a marker for chronic
heart failure, have also been associated with an increased
risk for death among patients hospitalized for AECOPD
without previously known ischemic heart disease [25].
During recent years, there are a few reports based on se-
lected patient populations with stable COPD, indicating
that troponin is increased [26] and associated with mor-
tality [16, 27] among COPD patients without known
heart disease. In recent years, the development and clin-
ical use of high-sensitivity cardiac troponin assays have
permitted the detection of myocardial injury more
widely [28]. In a recent study of 88 patients hospitalized
for AECOPD with elevated hs-cTnI, coronary angiog-
raphy detected ischemic heart disease in two-thirds, and
half of these patients underwent percutaneous coronary
intervention [28], supporting the assumption that, at
least in this setting, elevated hs-cTnI is associated with
subclinical ischemic heart disease.
The diagnostic threshold for myocardial infarction
using our high-sensitivity cTnI assay is 34 ng/L in men
and 16 ng/L in women [13]. However, hs-cTnI is in-
creasingly being used to evaluate cardiovascular risk at
concentrations well below the diagnostic threshold. The
optimal threshold for risk stratification continues to be
debated, but the largest study performed to date,
demonstrated that individuals in the Emergency Depart-
ment with hs-cTnI concentrations < 5 ng/L are at very
low risk of both short and long-term cardiac events [11].
Moreover, also in stable COPD patients participating in
a randomized controlled trial, the same threshold identi-
fied patients at low or high risk of cardiovascular death
[13]. However, cardiovascular disease or risk factors
were inclusion criteria in this study, and the study popu-
lation was limited to patients with moderate COPD
(FEV1 ≥ 50 and ≤ 70% of predicted) having dyspnea cor-
responding to mMRC ≥2 and a smoking history of ≥10
pack-years. Still to date, this approach to risk stratifica-
tion has not been evaluated in a less selected group of
individuals with COPD and, the generalizability of this
approach to population-based COPD cohorts has not
been known.
During the observation period in the current study,
mortality was nearly three-times higher among individ-
uals with COPD and hs-cTnI concentrations ≥5 ng/L
and was more than four times higher in those with add-
itional signs of ischemia on the electrocardiogram, com-
pared to those without these biomarkers, even after
adjusting for established cardiovascular risk factors. Fur-
thermore, this increase in risk was independent of
COPD severity and smoking habits. Importantly, despite
individuals with predominantly mild-moderate COPD
(See figure on previous page.)
Fig. 2 Survival among individuals with a COPD and b normal lung function, respectively, illustrated by Kaplan Meier curves by categories of cardiac
biomarkers based on hs-cTnI and ischemic ECG abnormalities (I-ECG). Due to limited sample size at the end of follow-up, one subject that deceased
after 2100 days is not included in Fig. 2 A, due to an unproportionate effect on the curve for hs-cTnI > 5 ng/L alone. This did not affect the Log Rank p-
value. (I-ECG includes Major Q/QS wave, major isolated ST-T abnormality, Minor Q wave plus major ST-T and minor isolated Q wave)
a b
Fig. 3 Forest plots illustrating mortality risk among individuals with a COPD and b normal lung function, respectively, by categories of cardiac
biomarkers based on hs-cTnI and ischemic ECG abnormalities (I-ECG). Multivariate Cox regression analyses of risk factors for death expressed as
HR;95% CI with “no cardiac biomarker” as reference, adjusting for age, sex, smoking habits and diabetes mellitus
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within the investigated population, abnormal cardiac
biomarkers were common; every fourth individual had
hs-cTnI ≥5 ng/L, and almost one in 10 had both elevated
hs-cTnI and ischemic ECG abnormalities.
Restricting our analyses to individuals with COPD
without reported ischemic heart disease supported our
hypothesis; the increased risk of death associated with
an elevated hs-cTnI concentration alone or in combin-
ation with ischemic ECG abnormalities persisted. Our
observations imply that these cardiac biomarkers may
identify individuals with unrecognized cardiac disease of
prognostic importance.
Both ischemic ECG abnormalities and troponin are in-
dependently known to be risk markers for mortality,
both among individuals with COPD [7, 16, 29] and in
the general population [30, 31]. However, the impact of
the combination of these markers has rarely been inves-
tigated. This study shows a difference in the risk profile
between individuals with COPD and NLF. Therefore, we
hypothesize that I-ECG represents a past event, that in-
creases long-term risk, while circulating hs-cTnI indi-
cates an ongoing subclinical myocardial disease that, in
combination with a chronic airway obstruction, nega-
tively affects the survival at a five-year perspective. Yet,
the mechanisms behind the impact of hs-cTnI in COPD
are still mainly unknown [32]. Future research is re-
quired to understand the relationship between these bio-
markers and coronary or structural heart disease among
individuals with COPD. Henceforth, this may contribute
to the development of an algorithm to identify individ-
uals with COPD in the general population at increased
risk in whom specific treatment and preventive measures
for cardiovascular disease could be introduced. Whilst
the numbers of deceased in each of the biomarker
groups in the current study were limited, still around
70% of the deaths among those with COPD were cardio-
vascular, compared with 53% among those without any
biomarkers. Yet, death certificates are to a great extent
based on clinical diagnosis and, thus, potential subclin-
ical cardiovascular disease, assumed to associate with el-
evated biomarkers under study, will therefore remain
undetected [33].
The strength of the current study is the large
population-based COPD cohort identified by post-
bronchodilator spirometry according to the GOLD
guidelines [6], and with a distribution of disease severity
dominated by mild to moderate COPD, as in other
population-based studies [34, 35]. The cohort is thus
considered representative for COPD in the population
and under-diagnosis of COPD [2, 6] is not expected to
affect the results. Further strengths are the use of well-
validated methods; a structured interview following a
validated questionnaire [36] Minnesota coding of ECG
[18] and a well validated high-sensitivity cTnI assay [12].
However, there are some limitations that merit discus-
sion. The prevalence of ischemic heart disease and dia-
betes mellitus was based on interview data and not on
medical records, and we do not have data on other
known risk factors, such as blood pressure and total
cholesterol. Still, there is known to be fairly good agree-
ment between self-reported data and medical records on
the comorbid conditions evaluated in the current study,
cardiovascular disease and diabetes mellitus [37–39].
Whilst information on hypertension would also be of
importance, self-reported data on hypertension have a
fairly low validity [40] and were thus not used. The
blood samples were collected during epidemiological
fieldwork and stored at -20 °C, but we do not anticipate
that troponin concentrations will have changed during
storage and have previously reported that hs-cTnI levels
predicted long-term cardiovascular events from samples
stored for 20 years [10]. Impaired renal function may
affect troponin levels, but data on renal function were
not available in this study. Yet, in a large population-
based study, there were no differences in unadjusted
comparisons and, also in adjusted analyses, those with
mild airway obstruction had similar mean glomerular fil-
tration ratio as those with normal lung function (89.1 vs.
89.6 ml/min/1.73 m2, p = 0.619), while those with moder-
ate/severe/very severe airway obstruction had slightly
lower mean value (87.6 ml/min/1.73 m2, p = 0.015) [41].
Our study included mainly mild to moderate COPD and
we believe that adjustment for renal function would
hardly affect the results. The OLIN COPD study was de-
signed shortly after the shift of the millennium, when
the fixed ratio criterion was generally accepted to define
airway obstruction in COPD. It is recognized that the
fixed ratio may overestimate COPD among elderly non-
smoker [42], and the lower limit of normal (LLN) criter-
ion for COPD is nowadays recommended in epidemio-
logical studies. Still, most clinical guidelines use the
fixed ratio criterion for COPD [6], thus the results are
highly clinically relevant and applicable in every-day care
for COPD.
Conclusion
In this study, elevated hs-cTnI concentrations in com-
bination with signs of myocardial ischemia on the elec-
trocardiogram were associated with a more than
fourfold increased risk of death in a population-based
COPD-cohort, independent of disease severity. This in-
creased risk was of similar magnitude also among those
with COPD, but without known ischemic heart disease.
Thus, these cardiac biomarkers may indicate the pres-
ence of undiagnosed and prognostically important car-
diovascular disease among individuals with COPD and
should be further evaluated for screening and risk mod-
eling at a population level.
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